AnPac: Rises on positive data from cancer monitoring technology study

Fresh2

04/09/2020 13:05

** U.S.-listed shares of Chinese biotech co  ANPC.O  rise
20.62% to 5.79% premarket
    ** Co reports positive data from a multi-year lung cancer
prognosis and recurrence study that began in 2014  urn:newsml:reuters.com:*:nGNXbbGC4X
    ** Says 1,000 patients were tested using co's cancer
differentiation analysis (CDA) technology for prognosis and to
evaluate cancer recurrence from initial diagnosis to surgery,
chemotherapy and other treatments, and remission 
    ** Early results indicate the CDA technology, which measures
bio-physical signals in the blood, could be a viable tool to
measure the effectiveness of the treatment and monitor
recurrence following remission

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))